Pinatuzumab Vedotin Usage And Synthesis

Uses

Pinatuzumab vedotin, an antibody-drug conjugate (ADC), is a CD22 humanized monoclonal antibody Pinatuzumab (HY-P99230) conjugated to VcMMAE (HY-15575). Pinatuzumab vedotin has antitumor activities[1].

References

[1] Ranjana H Advani, et al. Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. Clinical Trial Clin Cancer Res. 2017 Mar 1;23(5):1167-1176. DOI:10.1158/1078-0432.CCR-16-0772

Pinatuzumab Vedotin(1313706-14-7)Related Product Information

• Omburtamab
• Racotumomab
• Ganitumab
• Nurulimab
• Secukinumab
• Gemtuzumab
• Eldelumab
• Dacliximab
• Semorinemab
• Raxibacumab